Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 22.98 USD -5.35% Market Closed
Market Cap: 1.1B USD

Urogen Pharma Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Urogen Pharma Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Interest Income Expense
-$7.6m
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Interest Income Expense
$254k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Interest Income Expense
$57k
CAGR 3-Years
-81%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
N
Neurosense Therapeutics Ltd
NASDAQ:NRSN
Interest Income Expense
-$43k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Interest Income Expense
-$587k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Matricelf Ltd
TASE:MTLF
Interest Income Expense
₪533k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
29.28 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Urogen Pharma Ltd's Interest Income Expense?
Interest Income Expense
-7.6m USD

Based on the financial report for Sep 30, 2025, Urogen Pharma Ltd's Interest Income Expense amounts to -7.6m USD.

What is Urogen Pharma Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-17%

Over the last year, the Interest Income Expense growth was -46%. The average annual Interest Income Expense growth rates for Urogen Pharma Ltd have been -17% over the past three years .

Back to Top